Welcome to our dedicated page for NUTRA PHARMA SEC filings (Ticker: NPHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NUTRA PHARMA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NUTRA PHARMA's regulatory disclosures and financial reporting.
NUTRA PHARMA CORP (NPHC) reports a change in control driven by a transfer of preferred stock voting power. On August 21, 2026, Rik Deitsch transferred 12,000,000 shares of the company’s Series B Preferred Stock to Pure Raw Supplies, LLC as a gift and for no consideration. These Series B shares carry supermajority voting rights that allow the holder to control the outcome of substantially all matters submitted to stockholders. As a result, Pure Raw Supplies, LLC became the controlling stockholder of the company on that date, holding 62.63% of the total voting power of Nutra Pharma’s outstanding capital stock, voting power that had previously been held by Rik Deitsch.
NUTRA PHARMA CORP (NPHC) has a new large shareholder disclosure for its Series B Preferred Shares. Pure Raw Supplies, LLC, a Florida pharmaceutical consulting company, reports beneficial ownership of 12,000,000 Series B Preferred Shares, representing 100% of that class.
The shares were acquired on August 21, 2026 via a bona fide gift from Rik Deitsch, with no cash consideration or borrowed funds used. Pure Raw Supplies states it holds the shares for investment purposes and reports no current plans or proposals involving corporate actions such as mergers, asset sales, or changes in control. No contracts, arrangements, or other relationships regarding Nutra Pharma securities are disclosed beyond this ownership.
NUTRA PHARMA CORP (NPHC) had an initial ownership report filed by Pure Raw Supplies, LLC. The reporting entity is identified as a ten percent owner and discloses direct beneficial ownership of 12,000,000 Series B Preferred Shares. This Form 3 records holdings only, with no new transactions reported.
Nutra Pharma Corp (NPHC) insider and ten percent owner Rik J. Deitsch reported a bona fide gift of 12,000,000 shares of Series B Preferred Stock on 2026-08-21, leaving him with 0 Series B Preferred shares reported after the transaction. He continues to hold 43,298,859 shares of Common Stock directly.
NUTRA PHARMA CORP (NPHC) reports very weak financials for the quarter and six months ended June 30, 2026. The company generated modest product revenue, with net sales of $34,463 and related-party sales of $23,459 in the quarter, and continues to post negative gross margins after operating expenses. For the six months, net sales were $61,709 and related-party sales $44,427, while the net loss widened sharply to $4,408,447 from $1,035,346 a year earlier, driven largely by a $3,526,007 loss from changes in the fair value of convertible notes and derivatives.
The balance sheet is highly stressed: total assets were only $622,863 versus total liabilities of $21,831,616, resulting in a stockholders’ deficit of $21,208,753. Current liabilities of $21,696,808 include $12,573,897 of debt, most of which is in default, with $4,495,723 of convertible notes carried at fair value and $2,037,134 of derivative liabilities. Cash was $0 at June 30, 2026, and operating activities used $579,014 of cash in the first half, funded mainly by new high-cost convertible borrowings and receivables financings.
Management states there is substantial doubt about NPHC’s ability to continue as a going concern, citing recurring losses, a working capital deficit of $21,233,689, extensive indebtedness in default, and reliance on debt and equity funding that has not been sufficient to execute its business plan. The common stock trades on the OTC Expert Market, which the company notes limits its ability to raise capital. A very large overhang of deeply discounted, defaulted convertible notes and derivative features could lead to significant dilution if conversions occur.
Nutra Pharma Corp. reported a net loss of $459,675 for the three months ended March 31, 2026, narrower than the $1,404,923 loss a year earlier. Net sales were $27,246 and net sales to a related party added $20,968, both down from $73,974 and $36,420 in the prior-year period.
Operating expenses were $398,224, producing a loss from operations of $379,249. A $140,500 gain on settlement of debt partly offset interest and derivative fair-value charges, reducing total other expenses. Cash increased to $21,844 as of March 31, 2026, but operations used $327,791 of cash in the quarter.
The balance sheet remains highly leveraged. Total assets were $616,518 versus total liabilities of $17,878,499, creating a stockholders’ deficit of $17,261,981. The company discloses a working capital deficit of $17,243,345, significant indebtedness in default and extensive convertible notes, many at deep discounts to market.
Management states there is substantial doubt about Nutra Pharma’s ability to continue as a going concern without new financing and improved profitability. As of May 29, 2026, there were 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding. The company has also accrued a legal settlement of $680,235 arising from a final judgment in an SEC enforcement action.
Nutra Pharma Corp filed its annual report detailing a biopharmaceutical business focused on venom-derived pain products like Nyloxin and Pet Pain-Away and early-stage drug candidates for autoimmune, viral and neurological diseases. The company reported 2025 revenue of $385,307 and a net loss of $2,047,392, following 2024 revenue of $392,150 and a net loss of $1,285,663. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing an accumulated deficit of $78,278,529, a working capital deficit of $16,813,637, and negative operating cash flow. Nutra Pharma highlights Orphan Drug Designation for its RPI‑78M candidate in pediatric multiple sclerosis and outlines plans for future clinical trials and international expansion, all dependent on obtaining adequate financing and higher product sales.
Nutra Pharma Corp. reported modest revenue but continued heavy losses in its quarter ended September 30, 2025. Net sales for the nine months were $228,748, up from $164,436 a year earlier, yet the company posted a nine‑month net loss of $1,558,866.
Nutra Pharma ended the period with cash of only $3,603 and total assets of $709,853, against total liabilities of $17,060,633. Stockholders’ deficit widened to $16,350,780, and management disclosed a working capital deficit of $16,377,977 and substantial doubt about the company’s ability to continue as a going concern.
The company relies heavily on debt and equity funding, including numerous convertible notes, many of which are in default or under negotiation for settlement. As of April 6, 2026, there were 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding, reflecting significant leverage and dilution risk.
Nutra Pharma Corp reports Q2 2025 results showing net income of $369,577, reversing a prior-year quarterly loss, largely due to a $704,622 gain from changes in the fair value of convertible notes and derivatives and a $53,526 gain on debt settlements.
Core operations remain weak. For the three months ended June 30, 2025, net sales were $84,532 plus $37,611 to a related party, generating gross profit of only $75,628 against selling, general and administrative expenses of $366,157, resulting in a loss from operations of $290,529. For the six-month period, the company recorded a net loss of $1,035,346.
The balance sheet is highly leveraged, with total assets of $859,068 versus total liabilities of $16,692,328, including $9,345,780 of current debt and $924,516 of derivative liabilities. Stockholders’ deficit was $15,833,260, and the accumulated deficit reached $77,266,483.
Liquidity is strained: cash was only $79,069 at June 30, 2025, after using $693,376 in operating cash during the first half, funded mainly by $810,056 of new convertible notes and officer loans. Management discloses a working capital deficit of $15,888,753, numerous defaulted debts, dependence on external financing, and explicitly states there is substantial doubt about the company’s ability to continue as a going concern, exacerbated by its common stock trading on the OTC Market Group’s Expert Market, which restricts capital-raising options.